Teknova Introduces Proprietary Express-Tek℠ Production Service and Expanded Manufacturing Grade Options to Expedite Novel Therapy Development
Teknova (NASDAQ: TKNO) has launched two new offerings to enhance product customization and expedite novel therapy development:
- Express-Tek℠ Production: A proprietary service that reduces custom product turnaround time by an average of two weeks, allowing products to enter production in days instead of weeks.
- RUO+ Manufacturing Grade: A new grade bridging the gap between research and clinical-grade production, providing a seamless and cost-effective option for scaling from discovery to clinical manufacturing.
These offerings aim to accelerate therapeutic development by providing faster manufacturing, delivery of critical reagents, and flexible scaling options for customers transitioning from research to clinical trials.
Teknova (NASDAQ: TKNO) ha lanciato due nuove offerte per migliorare la personalizzazione dei prodotti e accelerare lo sviluppo di terapie innovative:
- Produzione Express-Tek℠: Un servizio proprietario che riduce il tempo di attesa per prodotti personalizzati in media di due settimane, consentendo l'ingresso in produzione in pochi giorni anziché in settimane.
- Grado di Fabbricazione RUO+: Un nuovo grado che colma il divario tra la produzione per la ricerca e quella clinica, offrendo un'opzione fluida e conveniente per scalare dalla scoperta alla produzione clinica.
Queste offerte mirano ad accelerare lo sviluppo terapeutico fornendo una produzione più rapida, la consegna di reagenti critici e opzioni di scalabilità flessibili per i clienti che passano dalla ricerca agli studi clinici.
Teknova (NASDAQ: TKNO) ha lanzado dos nuevas ofertas para mejorar la personalización de productos y acelerar el desarrollo de nuevas terapias:
- Producción Express-Tek℠: Un servicio propietario que reduce el tiempo de entrega de productos personalizados en un promedio de dos semanas, permitiendo que los productos entren en producción en días en lugar de semanas.
- Grado de Fabricación RUO+: Un nuevo grado que cierra la brecha entre la producción de investigación y la de grado clínico, proporcionando una opción fluida y rentable para escalar desde el descubrimiento hasta la fabricación clínica.
Estas ofertas tienen como objetivo acelerar el desarrollo terapéutico al proporcionar una fabricación más rápida, entrega de reactivos críticos y opciones de escalado flexibles para los clientes que pasan de la investigación a los ensayos clínicos.
테크노바 (NASDAQ: TKNO)는 제품 맞춤화를 향상하고 새로운 치료 개발을 가속화하기 위해 두 가지 새로운 서비스를 출시했습니다:
- 익스프레스-텍℠ 생산: 맞춤형 제품의 평균 리드 타임을 약 2주 단축시키는 독점 서비스로, 제품이 주가 아닌 며칠 만에 생산에 들어가도록 합니다.
- RUO+ 제조 등급: 연구 등급과 임상 등급 생산 사이의 간극을 줄여주며, 발견에서 임상 제조로의 전환을 위한 원활하고 비용 효율적인 옵션을 제공합니다.
이러한 서비스는 제조 속도를 높이고, 중요한 시약의 배송을 지원하며, 연구에서 임상 시험으로 전환하는 고객을 위한 유연한 확장 옵션을 제공하여 치료 개발을 가속화하는 것을 목표로 합니다.
Teknova (NASDAQ: TKNO) a lancé deux nouvelles offres pour améliorer la personnalisation des produits et accélérer le développement de nouvelles thérapies :
- Production Express-Tek℠: Un service propriétaire qui réduit le délai d'exécution des produits personnalisés d'environ deux semaines, permettant aux produits d'entrer en production en quelques jours plutôt qu'en semaines.
- Grade de Fabrication RUO+: Un nouveau grade qui comble le fossé entre la production de recherche et celle de niveau clinique, offrant une option fluide et rentable pour passer de la découverte à la fabrication clinique.
Ces offres visent à accélérer le développement thérapeutique en offrant une fabrication plus rapide, la livraison de réactifs critiques et des options d'évolutivité flexibles pour les clients qui passent de la recherche aux essais cliniques.
Teknova (NASDAQ: TKNO) hat zwei neue Angebote ins Leben gerufen, um die Produktanpassung zu verbessern und die Entwicklung neuer Therapien zu beschleunigen:
- Express-Tek℠ Produktion: Ein proprietärer Service, der die Bearbeitungszeit für maßgeschneiderte Produkte im Durchschnitt um zwei Wochen verkürzt und es ermöglicht, dass Produkte in Tagen und nicht in Wochen in die Produktion gehen.
- RUO+ Fertigungsgrad: Ein neuer Grad, der die Lücke zwischen der Forschung und der klinischen Produktion schließt und eine nahtlose sowie kosteneffektive Möglichkeit bietet, von der Entdeckung zur klinischen Herstellung zu skalieren.
Diese Angebote zielen darauf ab, die therapeutische Entwicklung zu beschleunigen, indem sie schnellere Herstellungsprozesse, die Lieferung kritischer Reagenzien und flexible Skalierungsoptionen für Kunden bieten, die von der Forschung zu klinischen Prüfungen übergehen.
- Introduction of Express-Tek℠ Production service, reducing custom product turnaround time by an average of two weeks
- Launch of RUO+ manufacturing grade, providing a cost-effective option for scaling from research to clinical production
- Expansion of product customization options, potentially attracting more customers and increasing market share
- None.
Insights
Teknova's introduction of Express-Tek℠ Production and RUO+ grade is a strategic move to address key pain points in the biotech industry. The expedited production service could be a game-changer for companies racing to bring therapies to market, potentially
The RUO+ grade fills a important gap between research and clinical production, potentially streamlining the transition process for customers. This could lead to increased customer retention and higher value contracts as clients scale up their operations. While these innovations are promising, their financial impact remains to be seen. Investors should monitor adoption rates and any changes in Teknova's market share in the coming quarters.
Teknova's new offerings address critical bottlenecks in the drug development pipeline. Express-Tek℠ Production's guarantee is particularly noteworthy, as it demonstrates confidence in their capabilities and could be a strong selling point. The RUO+ grade is an innovative solution to a common industry challenge, potentially reducing regulatory hurdles and costs for clients transitioning from research to clinical trials.
These developments could position Teknova as a preferred partner for biotech companies, especially those working on novel therapies with accelerated timelines. However, the success of these offerings will depend on Teknova's ability to maintain quality while increasing speed and flexibility. Investors should watch for partnerships or collaborations with leading biotech firms as indicators of market acceptance.
Express-TekSM Production enables customers to have their products enter production in days instead of weeks, significantly shortening turnaround time
New manufacturing grade, RUO+, provides a seamless and cost-effective option for customers as they transition from RUO to GMP
HOLLISTER, Calif., Aug. 13, 2024 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today launched two new offerings to provide customers with increased product customization options: Express-TekSM Production, to expedite the manufacturing and delivery of critical customer reagents, and a new manufacturing grade, RUO+, that enables customers to scale efficiently from discovery through process development and into clinical manufacturing.
“Our focus is to make solutions possible for our customers, and our thoughtful team continues to find innovative and impactful ways to help make therapeutic development easier and faster,” said Stephen Gunstream, President and Chief Executive Officer. “With the launch of our most recent offerings, we’re providing even more ways for our customers to customize and tailor their reagent manufacturing and accelerate the introduction of novel therapies. Express-Tek Production enables custom products to enter production in days instead of weeks. Teknova is already a leader in turnaround time for custom reagents, and we know how important it is for our customers to get critical products as quickly as possible. And, with Express-Tek, customers have our guarantee – if we don’t hit our date, then we’ll cover the expediting fee.”
Express-Tek Production is an expedited, proprietary service offering for customers with compressed timelines that reduces overall turnaround time of custom products by an average of two weeks, without compromising quality. By opting to pre-order raw materials, select prioritized manufacturing to secure the next spot in line for production, or choose expedited shipping options, Express-Tek Production helps customers get the products they need as soon as possible, guaranteed.
“We’re also introducing a new manufacturing grade to provide our customers with additional flexibility as they scale from research through commercialization,” continued Mr. Gunstream. “This new grade, called ‘RUO+’, is unique to Teknova and combines research-grade flexibility with clinical-grade production. We’ve heard from our customers that not having the right manufacturing grade at the right time can slow down their development by complicating process or technology transfer. The availability of RUO+ will allow them to scale seamlessly as they work towards a clinical trial.”
Teknova’s new manufacturing grade, RUO+, is an efficient and cost-effective solution that bridges the gap between research- and clinical-grade production. With RUO+, custom reagents are manufactured using the same validated facilities, equipment, and processes as GMP-grade products, providing comparable quality without the added documentation and testing requirements that GMP demands. The addition of RUO+, alongside Teknova’s pre-existing research- and GMP-grade options, equips novel therapy developers with a complete range of manufacturing grades for wherever they are in the clinical development pipeline.
Both Express-Tek Production and RUO+ are available starting today. Customers can select and include either offering as part of the custom reagent order process, which can be initiated by phone, email, or by using Teknova’s online custom order form.
For more information about Express-Tek Production, click here.
For more information about Teknova’s manufacturing grades, including RUO+, click here.
ABOUT TEKNOVA
Teknova makes solutions possible. Since 1996, Teknova has been innovating the manufacture of critical reagents for the life sciences industry to accelerate the discovery and development of novel therapies that will help people live longer, healthier lives. We offer fully customizable solutions for every stage of the workflow, supporting industry leaders in cell and gene therapy, molecular diagnostics, and synthetic biology. Our fast turnaround of high-quality agar plates, microbial culture media, buffers and reagents, and water helps our customers scale seamlessly from RUO to GMP. Headquartered in Hollister, California, with over 200,000 square feet of state-of-the-art facilities, Teknova’s modular manufacturing platform was designed by our team of scientists, engineers, and quality control experts to efficiently produce the foundational ingredients for the discovery and commercialization of novel therapies.
Investor Contact
Matt Lowell
Chief Financial Officer
matt.lowell@teknova.com
+1 831-637-1100
Media Contact
Jennifer Henry
Senior Vice President, Marketing
jenn.henry@teknova.com
+1 831-313-1259
FAQ
What is Teknova's new Express-Tek℠ Production service for TKNO stock investors?
How does Teknova's new RUO+ manufacturing grade benefit TKNO shareholders?
When will Teknova's Express-Tek℠ Production and RUO+ services be available for TKNO customers?
How might Teknova's new offerings impact TKNO stock performance?
